In the second half (H2) of 2021, venture financing deals increased by 14.3% from the same period in 2020.
But this marks a deceleration in growth from the 80.6% increase in deals seen from the first six months (H1) of 2020 to the same period in 2021.
During this time, the region that saw the biggest increase in the number of deals was Europe.
Deals rose by 375% in the region.
From the H2 of 2020 to the H2 of 2021, the largest regional increase in deals was seen in North America.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe region saw a 31% increase in deals.
During H2 of 2021, venture financing deals accounted for 13.5% of deals taking place in the sector. This represents an increase from the figure of 4.7% in H2 of 2020.
GlobalData's deals database is a comprehensive repository that looks at mergers, acquisitions, venture financing, equity offerings, asset transactions, partnerships and debt offerings taking place daily between thousands of companies across the world.
The database details key deal information, such as deal summary, deal rationale, deal financials, parties involved, advisors and deal payment modes.
By tracking the proportion of various types of deals in each sector we can gauge which sectors are seeing growth and where others are struggling.
The highest value venture financing deal that took place in 2021 (where the deal value was known) was the $225 million secured by pharmatech company Exscientia.
The database states that the rationale behind this deal was as follows: "The company intends to use the proceeds to advance its proprietary pipeline through clinical testing as well as to continue expanding the technology platform toward autonomous drug design."